Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release

Journal of Clinical Pharmacology

Volumn 49, Issue 11, 2009, Pages 1318-1330

  Boom, Sandra ^a,b   Talluri, Krishna ^b,c,d   Janssens, Luc ^a   Remmerie, Bart ^a   De Meulder, Marc ^a   Rossenu, Stefaan ^a   Van Osselaer, Nancy ^a   Eerdekens, Marielle ^a   Cleton, Adriaan ^a,b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c Pharma Plus ^*  (Netherlands)

^d Compass Consulting International ^*  (United States)

Author keywords

Dose proportionality; Paliperidone; Pharmacokinetics

Indexed keywords

PALIPERIDONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DYSKINESIA; DYSTONIA; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERKINESIA; HYPOTENSION; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCLE HYPERTONIA; NORMAL HUMAN; POSITIONAL DIZZINESS; SINGLE DRUG DOSE; SPEECH DISORDER; STEADY STATE; TREMOR;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PYRIMIDINES; RANDOM ALLOCATION;

EID: 70350424360     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009339190     Document Type: Article

References (21)

1. Kessler RC, Birnbaum H, Demler O, et al. The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry. 2005;58:668-676. 2. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2:e141.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Text rev, 4 th ed. Washington, DC: 2000: 297-313.
3. American Psychiatric Association. Practice Guidelines for the Treatment of Patients With Schizophrenia. 2 nd ed. Washington, DC: American Psychiatric Association ; 2004.
4. Davis JM, Chen N., Glick ID A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003 ; 60: 553-564.
5. Ascher-Svanum H., Kennedy JS, Lee D., Haberman M. The rate, pattern, and cost of use of antiparkinsonian agents among patients treated for schizophrenia in a managed care setting. Am J Manag Care. 2004 ; 10: 20-24.
6. Schotte A., Janssen PF, Gommeren W., et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 ; 124: 57-73.
7. Megens Aahp, Awouters Fhl. In vivo pharmacological profile of 9-hydroxyrisperidone the major metabolite of the novel antipsychotic risperidone. Drug Dev Res. 2004 ; 33: 399-412.
8. Karlsson P., Dencker E., Nyberg S., et al. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects. Eur Neuropsychopharmacol. 2005 ; 15 (suppl 3). S386.
9. Kane J., Canas F., Kramer M., et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007 ; 90: 147-161. (Pubitemid 46178537)
10. Marder SR, Kramer M., Ford L., et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007 ; 62: 1363-1370.
11. Davidson M., Emsley R., Kramer M., et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007 ; 93: 117-130.
12. Kramer M., Simpson G., Maciulis V., et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007 ; 27: 6-14.
13. Janssen Pharmaceuticals. Invega prescribing information. Paliperidone extended release tablets. Titusville, NJ. http://www.invega.com/invega/shared/ pi/invega.pdf#zoom=100. Accessed November 2007.
14. Cleton A., Rossenu S., Vermeulen A., et al. A pharmacokinetic model to document the interconversion between paliperidone enantiomers. Clin Pharmacol Ther. 2006 ; 79: P55 ( PII - 72 ).
15. Rossenu S., Crauwels H., Cleton A., et al. Evaluation of the pharmacokinetics of several formulations of paliperidone. AAPS J. 2006 ;8(suppl 2): 1042.
16. Vermeir M., Naessens I., Remmerie B., et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos. 2008 ; 36: 769-779.
17. Remmerie BM, Sips LL, de Vries R., et al. Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 ; 783: 461-472.
18. Mannens G., Meuldermans W., Snoeck E., Heykants J. Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology (Berl). 1994 ; 114: 566-572.
19. Cleton A., Talluri K., Leempoels J., et al. No pharmacokinetic interaction between trimethoprim and pailperidone ER in healthy subjects. Clin Pharmacol Ther. 2006 ; 79: P22 ( PI - 58 ).
20. Rossenu S., Cleton A., Rusch S., et al. Extended-release formulation of paliperidone shows dose-proportional pharmacokinetics. AAPS J. 2006 ; 8 (suppl 2). T3123.
21. Cleton A., Rossenu S., Talluri K., et al. Comprison of pharmacodynamic parameters resulting from administration of paliperidone extended-release tablet formulations and an immedite release formulation of risperidone in patients with schizophrenia. Clin Pharm Ther. 2007 ; 81 (suppl 1). S61.